Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Receivables: 2010-2024

Historic Receivables for Anika Therapeutics (ANIK) over the last 15 years, with Dec 2024 value amounting to $24.3 million.

  • Anika Therapeutics' Receivables fell 25.45% to $23.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.8 million, marking a year-over-year decrease of 25.38%. This contributed to the annual value of $24.3 million for FY2024, which is 10.00% down from last year.
  • As of FY2024, Anika Therapeutics' Receivables stood at $24.3 million, which was down 10.00% from $27.0 million recorded in FY2023.
  • In the past 5 years, Anika Therapeutics' Receivables registered a high of $36.2 million during FY2022, and its lowest value of $24.1 million during FY2020.
  • For the 3-year period, Anika Therapeutics' Receivables averaged around $29.2 million, with its median value being $27.0 million (2023).
  • In the last 5 years, Anika Therapeutics' Receivables rose by 29.80% in 2021 and then fell by 25.41% in 2023.
  • Anika Therapeutics' Receivables (Yearly) stood at $24.1 million in 2020, then grew by 29.80% to $31.3 million in 2021, then climbed by 15.82% to $36.2 million in 2022, then dropped by 25.41% to $27.0 million in 2023, then decreased by 10.00% to $24.3 million in 2024.